メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
富山大学でコンテンツを検索
ホーム
プロファイル
研究部門
設備
プロジェクト
研究成果
データセット
受賞
活動
授業
Scopus著者プロファイル
林 龍二
教授, 博士(医学) 富山医科薬科大学 2000年3月
臨床腫瘍学講座
h-index
1532
被引用数
19
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1998 …
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
プロジェクト
(5)
研究成果
(104)
データセット
(2)
授業
(66)
類似のプロファイル
(6)
フィンガープリント
Ryuji Hayashiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Lung Cancer
85%
Progression-free Survival
53%
Immune Checkpoint Inhibitors
51%
Small Cell Lung Cancer
44%
Japan
41%
Lung Adenocarcinoma
41%
Hokushin Region
41%
Monotherapy
36%
Multi-institutional Survey
36%
Chemotherapy
35%
Immune Checkpoint Inhibitor Therapy
34%
Clinical Course
34%
Lung
33%
Older Men
32%
Human Lung Fibroblasts
32%
SRT1720
31%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
28%
Sirtuin 1 (SIRT1)
28%
Tumor
26%
Interstitial Pneumonia
24%
Interleukin-6
23%
Adverse Effects
22%
Prognostic Factors
22%
Lung Injury
22%
Induced Apoptosis
21%
Mikulicz's Disease
20%
Eosinophilic Pneumonia
20%
SIRT1 Activator
20%
C-Jun N-terminal Kinase Signaling
20%
Bronchiolitis
20%
Photo-cross-linker
20%
Ionizing Radiation
20%
Elderly Patients
20%
Bradykinin
20%
Alveolar Epithelial Cells
20%
Interleukin-8
20%
Pulmonary Sarcomatoid Carcinoma
20%
Cisplatin
18%
Tumor Cells
17%
MRNA Level
17%
Lung Cancer Patients
17%
Programmed Death-ligand 1 Expression
17%
Clinical Practice
17%
Confidence Interval
16%
Home Death
16%
Carboplatin
16%
Previously Untreated
16%
Overall Survival
16%
Cancer Patients
16%
Medicine and Dentistry
Lung Cancer
96%
Lung
70%
Non Small Cell Lung Cancer
61%
Immune Checkpoint Inhibitor
59%
Chemotherapy
43%
Disease
42%
Lung Adenocarcinoma
41%
Small Cell Lung Cancer
40%
Disease Course
34%
Retrospective Study
29%
Progression Free Survival
29%
Neoplasm
28%
Malignant Neoplasm
25%
Idiopathic Interstitial Pneumonia
24%
Bronchiolitis
24%
Tumor Cell
22%
Computer Assisted Tomography
20%
Löffler's Syndrome
20%
Immunoglobulin G4
20%
Mikulicz Disease
20%
Epithelial Cell
20%
Sirtuin1
20%
Prednisolone
20%
Monotherapy
18%
Recurrent Disease
18%
Epidermal Growth Factor Receptor
18%
Bronchiolitis Obliterans Organizing Pneumonia
17%
Adverse Event
16%
Carboplatin
15%
Evans Syndrome
15%
Sarcomatoid Carcinoma
15%
Metastatic Carcinoma
15%
Overall Survival
15%
Lung Carcinoma
14%
Thorax Radiography
14%
T-Helper Cell
14%
Symptomatic Treatment
13%
Fibrosis
13%
Messenger RNA
13%
Protein P53
13%
Amino Terminal Sequence
12%
Nivolumab
12%
Systemic Therapy
12%
Loss of Appetite
12%
Immunoglobulin Producing Cell
12%
Pleura Mesothelioma
12%
Comorbidity
12%
Cellular Infiltration
11%
Neutrophil
11%
Provocation Test
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
76%
Small Cell Lung Cancer
60%
Lung Cancer
51%
Progression Free Survival
46%
Chemotherapy
46%
Immune Checkpoint Inhibitor
44%
Epidermal Growth Factor Receptor
40%
Retrospective Study
39%
Monotherapy
35%
Neoplasm
34%
Adverse Event
31%
N [2 [3 (1 piperazinylmethyl)imidazo[2,1 B]thiazol 6 Yl]phenyl] 2 Quinoxalinecarboxamide
31%
Messenger RNA
27%
Overall Survival
24%
Protein P53
23%
Interleukin 6
23%
Programmed Death 1 Ligand 1
22%
Malignant Neoplasm
22%
Cytokine
21%
Phosphotransferase
21%
Ionizing Radiation
20%
Bradykinin
20%
Interleukin 8
20%
Disease
20%
Cisplatin
18%
Inflammation
18%
Asthma
17%
Lactate Dehydrogenase
16%
Recurrent Disease
15%
Durvalumab
12%
Hydrogen Peroxide
12%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Disease Course
12%
Radiation Pneumonia
11%
Mouse Model
11%
Carcinoma
10%
Glutamate Sodium
10%
Squamous Cell Lung Carcinoma
10%
Multidrug Resistance Associated Protein 1
10%
Diphtheria Toxin
10%
Chronic Obstructive Lung Disease
10%
Pleura Mesothelioma
10%
Creatinine
10%
Irinotecan
10%
Gelatinase A
10%
Fatty Liver
10%
Isoprenaline
10%
Doxorubicin
10%
Legionella
10%
Cystatin C
10%
